Medical/Pharmaceuticals
Pantai Hospital Kuala Lumpur Introduces Outpatient Parenteral Antimicrobial Therapy (OPAT) for Improved Patient Care
KUALA LUMPUR, Malaysia, Aug. 12, 2024 /PRNewswire/ -- Pantai Hospital Kuala
Lumpur (PHKL) has officially introduced its Outpatient Parenteral Antimicrobial
Therapy (OPAT) service, offering an innovative treatment option that enhances
patient care.
2024-08-13 08:53
1937
AI in the IVF Process is the Standard of Care at Virtus Fertility Centre Singapore
The technology developed by Virtus Health's scientists contributes to IVF medicine by shortening the time to a successful pregnancy and improving overall success rates. SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Virtus Fertility Centre Singapore (VFCS) announced that artificial intelligence (AI), ...
2024-08-13 08:44
1792
MediPortal Introduces AI for Practice Management in Australia
PERTH, Australia, Aug. 13, 2024 /PRNewswire/ -- MediPortal PTY LTD. (MediPortal) has launched an AI-powered practice intelligence platform for Australian medical practices, aiming to enhance efficiency and patient care. Developed as the brainchild of a practising general practitioner, this innov...
2024-08-13 08:30
1845
Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positive results from its Phase1b clinical study of LNK01004, a skin restricte...
2024-08-13 08:00
1842
Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program
* Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. onJuly 2, 2023 * Adalimumab-aaty's inclusion creates greater accessibility to treatments for Americans with inflammatory conditions...
2024-08-13 07:46
1607
Environmental Compliance and Pharmaceutical Quality Standards Pave the Way for Transformational Growth in Chromatography
SAN ANTONIO, Aug. 13, 2024 /PRNewswire/ -- Chromatography instruments and modular test equipment are revolutionising scientific analysis and industrial testing. By enabling precise separation and analysis of complex mixtures, chromatography plays a crucial role in ensuring pharmaceutical purity, ...
2024-08-13 01:30
1688
OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMension will acquire or secure commercialization rights inChina to a portfolio of Alcon dr...
2024-08-12 22:01
2510
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been granted Breakthrough Therapy Designation (BTD) bythe Center for Drug Evaluation (CDE) of China's...
2024-08-12 22:00
1934
Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics ( Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the reporting period, the company achieved operating revenue ofRMB 168 million, ...
2024-08-12 21:52
3033
VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism
* 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primarymulti-component endpoint compared to 0.0% for placebo (p <0.0001) * Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug. SHANGHAI, Aug. 12...
2024-08-12 21:00
1810
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.[1] The primary endpoint of superiority to placebo in a cognitive "attention composite" of three Cogstate computerized tests was not met with large improvements seen in both Xan...
2024-08-12 20:30
1833
AXA Study: Hong Kong workers buckling under high stress and poor mind health
More than 3 in 4 Hong Kong workers face mind health issues at work, with nearly half taking sick leave HONG KONG, Aug. 12, 2024 /PRNewswire/ -- The majority of the working population inHong Kong suffers from multiple mental health problems related to work, and disengagement is alarmingly high, a...
2024-08-12 18:19
2136
Sumedang Regency and Docquity Launch AI-Driven Health Platform to Tackle Tuberculosis, Stunting, and Hypertension
SUMEDANG, Indonesia, Aug. 12, 2024 /PRNewswire/ -- Docquity, a leading health tech company established in 2015, is proud to announce its expansion into the B2G sector with the launch of the Puskesmas AI platform in partnership with Sumedang Regency,West Java. This initiative builds on the success...
2024-08-12 15:00
1867
Milestone: Renal Nerve Mapping / Selective Renal Denervation (msRDN) System by SyMap Medical Ltd Approved for Treatment of Uncontrolled Hypertension in China
SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- On August 6, 2024, the msRDN System (SyMapCath I®/ SYMPIONEER S1®), developed by Suzhou/China-based SyMap Medical Ltd. (SyMap Medical), was approved by the National Medical Products Administration (NMPA) ofChina and granted a Class III Medical Devices ...
2024-08-12 13:55
1367
IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Two New Autoimmune Disease Indications
SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 12, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the investigation...
2024-08-12 13:52
1440
German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation
BAODING, China, Aug. 12, 2024 /PRNewswire/ -- A landmark German delegation, led by world-renowned stem cell expert Prof. Dato' Sri Dr.Mike Chan, concluded a three-day visit to Baoding,China, marking a significant step in international health cooperation. The visit, fromJuly 11-13, reciprocated an...
2024-08-12 12:08
1881
Hong Kong Breast Cancer Foundation charity walk "Pink Walk 2024" - "Walk for Breast Cancer, Together We Can"
20 October at The Peak HONG KONG, Aug. 12, 2024 /PRNewswire/ -- The Hong Kong Breast Cancer Foundation (HKBCF), is delighted to announce that its annual signature fundraising event"Pink Walk 2024" will take place on 20 October 2024 (Sunday) at The Peak,Hong Kong Island. Themed "Walk for Breast C...
2024-08-12 10:45
1630
Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 in patients with platinum-resistant ovarian cancer and patients with advanced HER2-positive (...
2024-08-12 10:18
1837
Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease
SHANGHAI, Aug. 9, 2024 /PRNewswire/ -- Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the launch ofAsia's first international multi-center clinical study of Percutaneous Pulmonary Artery ...
2024-08-09 17:09
4789
T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
Summary * T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer. * MT027, the product of target B7H3 received US FDA orphan drug d...
2024-08-08 20:00
2172
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
